Loading clinical trials...
Loading clinical trials...
Dorsolateral Versus Medial Prefrontal TMS for Depression
This study is aimed to help us learn about the effects of Transcranial Magnetic Stimulation at the forehead versus the left side of the head for treatment of Treatment Resistant Depression.
While transcranial magnetic stimulation (TMS) to the left dorsolateral prefrontal cortex (DLPFC) is an FDA approved treatment for depression, a growing and converging database suggests the medial prefrontal cortex (MPFC) may be even more critical to the neurobiology of depression and antidepressant treatment response. This study will compare the efficacy of high frequency transcranial madntic stimulation on these two sections of the brain.
Age
21 - 70 years
Sex
ALL
Healthy Volunteers
Yes
White River Junction VA Medical Center
White River Junction, Vermont, United States
Start Date
September 1, 2021
Primary Completion Date
August 1, 2022
Completion Date
September 1, 2022
Last Updated
May 13, 2021
TMS
DEVICE
Lead Sponsor
White River Junction Veterans Affairs Medical Center
NCT07360600
NCT06793397
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions